Barriers and motivations for participation in preventive vaccine clinical trials: Experience of 5 clinical research sites
- PMID: 31543417
- DOI: 10.1016/j.vaccine.2019.09.048
Barriers and motivations for participation in preventive vaccine clinical trials: Experience of 5 clinical research sites
Abstract
Recruitment in preventive vaccine trials (PVT) is challenging due to common barriers to clinical research and lack of vaccine confidence. Identifying determinants of participation can help to improve recruitment. A prospective survey was conducted in 5 French clinical investigational sites. People asked to participate in a PVT were given a questionnaire whether they decided to participate or not in the trial. A total of 341 people answered the survey: 210 accepting and 131 declining to participate in a PVT. Acceptors were significantly younger (38.5 vs 54.9 years old), more likely to be involved in early phase trials, had a higher level of education (p < 0.005) and a significantly better general opinion concerning vaccines (92.3% versus 72.3%, p < 0.005) compared with those who declined. Factors associated with acceptance or refusal were evaluated in 224 people in the 4 sites where both groups were included. In a multivariate analysis, three factors: older age, having heard about PVT through multiple sources and financial incentives were significantly associated with refusal to participate in the PVT. A generally favourable opinion of vaccines was associated with acceptance. The main motivation for participation was altruism (93.2%) whereas fear of side effects was at the forefront of the barriers (36.6%). Information given by the physician was a key point for decision-making in 70.2% of those who accepted. In brief, vaccine hesitancy may decrease recruitment in PVTs; reinforcing altruism and quality of information given are key points in acceptance of participation in PVT.
Keywords: Barriers; Motivations; Participation; Recruitment; Vaccine; Vaccine clinical trial.
Copyright © 2019. Published by Elsevier Ltd.
Similar articles
-
Primary physicians' attitudes toward their patients receiving a proposal to participate in a vaccine trial.Hum Vaccin Immunother. 2019;15(12):2969-2979. doi: 10.1080/21645515.2019.1625646. Epub 2019 Jun 26. Hum Vaccin Immunother. 2019. PMID: 31241393 Free PMC article.
-
Involving South Asian patients in clinical trials.Health Technol Assess. 2004 Oct;8(42):iii, 1-109. doi: 10.3310/hta8420. Health Technol Assess. 2004. PMID: 15488164 Review.
-
Motivation for participating in phase 1 vaccine trials: Comparison of an influenza and an Ebola randomized controlled trial.Vaccine. 2019 Jan 7;37(2):289-295. doi: 10.1016/j.vaccine.2018.11.014. Epub 2018 Dec 7. Vaccine. 2019. PMID: 30528592
-
Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand.AIDS. 1995 Sep;9(9):1079-83. doi: 10.1097/00002030-199509000-00015. AIDS. 1995. PMID: 8527082
-
Recruitment barriers for prophylactic vaccine trials: A study in Belgium.Vaccine. 2017 Dec 4;35(48 Pt B):6598-6603. doi: 10.1016/j.vaccine.2017.10.041. Epub 2017 Oct 23. Vaccine. 2017. PMID: 29074202 Review.
Cited by
-
Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic.Vaccine. 2020 Oct 21;38(45):7002-7006. doi: 10.1016/j.vaccine.2020.09.041. Epub 2020 Sep 17. Vaccine. 2020. PMID: 32988688 Free PMC article.
-
Factors affecting willingness to participate in vaccine clinical trials in an underdeveloped country: perspective from Nepal.Hum Vaccin Immunother. 2022 Nov 30;18(5):2051413. doi: 10.1080/21645515.2022.2051413. Epub 2022 Mar 30. Hum Vaccin Immunother. 2022. PMID: 35353657 Free PMC article.
-
Intention to participate in COVID-19 vaccine clinical trials in May 2021: a cross-sectional survey in the general French population.Hum Vaccin Immunother. 2022 Nov 30;18(5):2072630. doi: 10.1080/21645515.2022.2072630. Epub 2022 May 13. Hum Vaccin Immunother. 2022. PMID: 35561252 Free PMC article.
-
Characterization of Individuals Interested in Participating in a Phase I SARS-CoV-2 Vaccine Trial.Vaccines (Basel). 2021 Oct 19;9(10):1208. doi: 10.3390/vaccines9101208. Vaccines (Basel). 2021. PMID: 34696316 Free PMC article.
-
Barriers and facilitators of participation in syphilis vaccine trials: a qualitative analysis to inform trial design and community engagement in the United States.Sex Reprod Health Matters. 2024 Dec;32(1):2473199. doi: 10.1080/26410397.2025.2473199. Epub 2025 May 2. Sex Reprod Health Matters. 2024. PMID: 40052273 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical